Syros Pharmaceuticals, Inc.

Good morning and welcome to Xero's Pharmaceuticals 3rd Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Xero's website at www.xero's.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Karen Hunady. Director of Investor Relations and Corporate Communications at Cirrus. Please go ahead.

Thank you. This morning, we issued a press release announcing our third quarter 2023 financial results. The full release is available on the investor and media section of the Cirrus website at www.cirrus.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer, Conley Chee, our Chief Commercial Officer, Chief Business Officer, and incoming Chief Executive Officer, Dr. David Roth, our Chief Medical Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristen Stevens, our Chief Development Officer, is also on the call and will be available for Q&A. Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our quarterly report on Form 10-Q that we filed this morning our annual report on Form 10-K that we filed earlier in the year, and any other filings that we may make with the SEC in the future. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. With that, I'd now like to turn the call over to Nancy. Nancy? Thank you, Karen.

Good morning, everyone, and thank you for joining us. Today's call marks my last as the CEO of Ciros. In October, we announced my planned retirement as CEO and the appointment of Conley Chee as Ciros' next CEO. I am incredibly proud of the company we've built over the last 11 years. We have made tremendous progress toward our mission of translating breakthrough science into new medicine that can make a profound difference for patients on the foundation of a strong, experienced leadership team and a collaborative patient-focused culture. I look forward to supporting Cirrus in partnering with Conley and the team as I continue my service on Cirrus's board of directors. Following our strategic prioritization earlier this fall, Cirrus is a company with a singular focus. We are devoting our resources to the advancement of Tamiberitine, our oral, selective, and potent RAR-alpha agonist for the frontline treatment of hematologic malignancies. As Conley and David will detail this morning, we believe Tamiberitine has the opportunity to become the standard of care for higher-risk MDS in unfit AML patients with RARA overexpression. Tamiberitone has a differentiated profile. It is a biologically targeted agent that has demonstrated high complete response rates, a rapid time to response, and a favorable tolerability profile across multiple clinical trials. I am incredibly proud to have taken serose from a scientific discovery in 2014 to late stage development on the path to commercialization. As a company, we are approaching this important transformation with data from our first pivotal study in higher risk MDS to be reported next year and initial data from the randomized portion of our phase two study in AML that we plan to present in early December. As we prepare for our maturation into a commercial company, it is a natural time to transition leadership to Conley, our chief commercial and business officer, who is an expert at building effective commercial organizations and launching targeted oncology therapies. Conley has been a valuable member of our leadership team for over two years, informing all aspects of our business. Having worked with Conley during this time and during our transition over the last month, I am confident he will be an impactful and effective leader in this next stage for Cirrus. With that, I would like to turn the call over to Conley to provide some brief remarks. Conley?